Bayer(US:BAYRY) 生物世界·2025-10-30 04:21Core Insights - Bayer's commitment to innovation in China's biopharmaceutical sector is highlighted through the successful hosting of the first "Co-Creation New Drug" competition, recognizing six biotech companies for their groundbreaking innovations in oncology, cardiovascular diseases, kidney diseases, immunology, and new technology platforms [1][4][9]. Group 1: Event Overview - The "Bayer Prescription Drug China Open Innovation Day" was held on October 28, 2025, showcasing Bayer's focus on China's innovation and new drug development capabilities [1]. - The event featured discussions among global and local management, industry experts, research institutions, investment firms, and startups, emphasizing Bayer's commitment to integrating into China's pharmaceutical innovation ecosystem [1][3]. Group 2: Strategic Focus - Bayer is concentrating on key research areas, establishing a differentiated pipeline for long-term growth in oncology, cardiovascular diseases, kidney diseases, neurology, rare diseases, and immunology [3][4]. - The company aims to leverage external collaborations to enhance its drug development process, focusing on unmet medical needs and high-value potential areas [3][4]. Group 3: Winning Companies - Six biotech companies were recognized for their innovative achievements: - Zhihui Medicine focuses on overcoming tumor resistance mechanisms [5][13]. - Gaowei Medicine utilizes advanced algorithms for drug target identification [5][14]. - Aibelle is developing next-generation immunotherapies for solid tumors [5][15]. - Alpha Molecule targets GPCRs with an AI-driven platform [5][16]. - Shanghai Yinuo Pharmaceutical specializes in autoimmune and chronic inflammatory diseases [5][17]. - Yaoshu Technology employs organ-on-chip technology for drug discovery [5][18]. - These companies will receive various rewards and support from Bayer, including entry into the Bayer Co.Lab platform and mentorship from experts [5][10]. Group 4: Bayer's Global Strategy - Bayer views China as a core strategic market for global pharmaceutical innovation and is actively exploring diverse external collaborations [4][9]. - The company has established the Bayer Co.Lab platform to support local startups and early-stage innovations, fostering a collaborative ecosystem [10].